Creative Medical Technology completes ADAPT trial enrollment and treatment
Creative Medical Technology Holdings (CELZ) says it successfully completes enrollment and treatment across the entire FDA-cleared ADAPT trial, including the opioid cohort, advancing CELZ-201 (Olastrocel) toward RMAT evaluation and Phase 3 planning.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.